🔗 Share this article Patients Discontinuing Weight-Loss Jabs Put On Pounds Four Times Faster Than Those on Conventional Diets Obesity treatment involves ongoing approaches. New research indicates that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds far faster than those who halt conventional diet and exercise regimens. Findings released in a prominent health publication points out that while overweight individuals often shed a large proportion of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month once they quit. "Users buying these medications should be aware of the potential of rapid rebound weight gain when the treatment concludes," stated researcher Dr. Susan Jebb. This pace of recovery implies a return to pre-treatment mass in about a year and a half. Analyzing Treatments The research, which examined dozens of trials involving over 9,000 of patients, compared the outcomes of these new drugs with older methods. Researchers point out that people who shed pounds through lifestyle changes alone generally have a slower weight regain—around 100 grams monthly—after stopping. Understanding the Quick Regain Doctors propose the mechanism of the jabs is key to understanding the amplified rebound. GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates appetite. "Artificially providing the hormone levels far above than the body's typical production could lead to the system to produce less of its own natural GLP-1, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist. "Discontinuation of this hormone supplement leads to appetite is uncontrolled, making binge eating far more likely." A Chronic Disease? The NHS recommend the injections for people with weight-linked health risks, alongside prescribed diet and exercise modifications. Professionals contend that, given the likelihood of relapse, the treatment should be considered life-long. This perspective is echoed by drug manufacturers, who note that the results "highlight the chronic character of excess weight," akin to managing conditions like high blood pressure. Patient Accounts People who have discontinued the jabs report a powerful return of cravings. "It was like something activating and I was suddenly ravenous," described an individual. This challenge is exacerbated if patients have not established permanent dietary or behavioural modifications during therapy. Growing Adoption Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow. Adoption is more common among women than men. The 40s and 50s age group shows the highest level of interest. A large proportion access the drugs through private healthcare rather than public health services. In conclusion, clinicians caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on combined behavioural management.
Obesity treatment involves ongoing approaches. New research indicates that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds far faster than those who halt conventional diet and exercise regimens. Findings released in a prominent health publication points out that while overweight individuals often shed a large proportion of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month once they quit. "Users buying these medications should be aware of the potential of rapid rebound weight gain when the treatment concludes," stated researcher Dr. Susan Jebb. This pace of recovery implies a return to pre-treatment mass in about a year and a half. Analyzing Treatments The research, which examined dozens of trials involving over 9,000 of patients, compared the outcomes of these new drugs with older methods. Researchers point out that people who shed pounds through lifestyle changes alone generally have a slower weight regain—around 100 grams monthly—after stopping. Understanding the Quick Regain Doctors propose the mechanism of the jabs is key to understanding the amplified rebound. GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates appetite. "Artificially providing the hormone levels far above than the body's typical production could lead to the system to produce less of its own natural GLP-1, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist. "Discontinuation of this hormone supplement leads to appetite is uncontrolled, making binge eating far more likely." A Chronic Disease? The NHS recommend the injections for people with weight-linked health risks, alongside prescribed diet and exercise modifications. Professionals contend that, given the likelihood of relapse, the treatment should be considered life-long. This perspective is echoed by drug manufacturers, who note that the results "highlight the chronic character of excess weight," akin to managing conditions like high blood pressure. Patient Accounts People who have discontinued the jabs report a powerful return of cravings. "It was like something activating and I was suddenly ravenous," described an individual. This challenge is exacerbated if patients have not established permanent dietary or behavioural modifications during therapy. Growing Adoption Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow. Adoption is more common among women than men. The 40s and 50s age group shows the highest level of interest. A large proportion access the drugs through private healthcare rather than public health services. In conclusion, clinicians caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on combined behavioural management.